Patents Assigned to Serono Genetics Institute, S.A.
-
Patent number: 7442519Abstract: The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators. The invention also discloses biallelic markers located in the KCNQ2 gene and their use for diagnosing mental disorders.Type: GrantFiled: June 20, 2003Date of Patent: October 28, 2008Assignee: Serono Genetics Institute, S.A.Inventors: Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier, Isabelle Elias
-
Publication number: 20080249009Abstract: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.Type: ApplicationFiled: April 30, 2007Publication date: October 9, 2008Applicant: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Patent number: 7432056Abstract: The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.Type: GrantFiled: August 25, 2004Date of Patent: October 7, 2008Assignee: Serono Genetics Institute S.A.Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov, Annick Cohen
-
Patent number: 7432367Abstract: The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5? end and the 3? end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.Type: GrantFiled: May 19, 2005Date of Patent: October 7, 2008Assignee: Serono Genetics Institute, S.A.Inventor: Lydie Bougueleret
-
Patent number: 7427482Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.Type: GrantFiled: November 22, 2005Date of Patent: September 23, 2008Assignee: Serono Genetics Institute S.A.Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine
-
Publication number: 20080201789Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.Type: ApplicationFiled: March 18, 2008Publication date: August 21, 2008Applicant: SERONO GENETICS INSTITUTE S.A.Inventors: Gilbert Thill, Philippe Jais, Pascale Grel, Sandrine Mace
-
Publication number: 20080199883Abstract: The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.Type: ApplicationFiled: March 30, 2007Publication date: August 21, 2008Applicant: Serono Genetics Institute S.A.Inventors: Bernard Bihain, Barbara Bour, Lydie Bougueleret
-
Patent number: 7413875Abstract: The sequences of 5? ESTs and consensus contigated 5?ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs and consensus contigated 5?ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs and consensus contigated 5?ESTs. The 5? ESTs and consensus contigated 5?ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs and consensus contigated 5?ESTs. The 5? ESTs and consensus contigated 5?ESTs may also be used to design expression vectors and secretion vectors.Type: GrantFiled: September 15, 2003Date of Patent: August 19, 2008Assignee: Serono Genetics Institute S.A.Inventors: Jean-Baptiste Dumas Milne Edwards, Severin Jobert, Jean-Yves Giordano
-
Publication number: 20080182268Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: ApplicationFiled: March 27, 2008Publication date: July 31, 2008Applicant: SERONO GENETICS INSTITUTE S.A.Inventors: DANIEL COHEN, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
-
Publication number: 20080184381Abstract: The invention concerns the genomic DNA, cDNA, and polypeptide sequences of CanIon, a novel voltage gated ion channel protein. The invention also concerns biallelic markers of the CanIon gene. The CanIon gene may be used as a biological target for the treatment and diagnosis of schizophrenia, bipolar disorder, and other diseases and conditions.Type: ApplicationFiled: March 18, 2008Publication date: July 31, 2008Applicant: SERONO GENETICS INSTITUTE S.A.Inventors: Daniel Cohen, Ilya Chumakov, Anne-Marie Simon, Hadi Abderrahim
-
Patent number: 7405193Abstract: The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass in general. The muscle-related diseases or disorders envisaged to be treated by the methods of the invention include, but are not limited to, muscular dystrophy, and other conditions resulting in muscle atrophy or muscle wasting.Type: GrantFiled: May 22, 2001Date of Patent: July 29, 2008Assignee: Serono Genetics Institute S.A.Inventors: Harvey Lodish, Joachim Fruebis, Tsu-Shuen Tsao, Bernard Bihain
-
Patent number: 7402393Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GZIP polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: October 3, 2002Date of Patent: July 22, 2008Assignee: Serono Genetics Institute S.A.Inventors: Ilya Chumakov, Oxana Guerassimenko
-
Publication number: 20080168574Abstract: The present invention is directed to BAP28 polypeptides. BAP28 cDNA sequences encoding BAP28 polypeptides, to the genomic DNA sequence of the BAP28 gene as well as to regulatory regions located at the 5?- and 3?-ends of the BAP28 coding region. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the BAP28 gene useful in genetic analysis. The invention concerns an association of the BAP28-related biallelic markers with prostate cancer. Therefore, the invention contemplates the diagnostic and treatment methods of prostate cancer.Type: ApplicationFiled: July 12, 2007Publication date: July 10, 2008Applicant: Serono Genetics Institute S.A.Inventors: Caroline Barry, Lydie Bougueleret, Ilya Chumakov, Annick Cohen-Akenine
-
Patent number: 7393661Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.Type: GrantFiled: May 19, 2005Date of Patent: July 1, 2008Assignee: Serono Genetics Institute S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 7393663Abstract: The sequences of 5? ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5? ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5? ESTs. The 5? ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5? ESTs. The 5? ESTs may also be used to design expression vectors and secretion vectors.Type: GrantFiled: July 30, 2003Date of Patent: July 1, 2008Assignee: Serono Genetics Institute S.A.Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Bruno Lacroix
-
Patent number: 7385034Abstract: The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.Type: GrantFiled: December 9, 2002Date of Patent: June 10, 2008Assignee: Serono Genetics Institute S.A.Inventors: Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert
-
Patent number: 7371811Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: GrantFiled: June 6, 2005Date of Patent: May 13, 2008Assignee: Serono Genetics Institute S.A.Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
-
Patent number: 7358066Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.Type: GrantFiled: July 22, 2002Date of Patent: April 15, 2008Assignee: Serono Genetics Institute S.A.Inventors: Gilbert Thill, Philippe Jais, Pascale Grel, Sandrine Mace
-
Patent number: 7348406Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: January 15, 2002Date of Patent: March 25, 2008Assignee: Serono Genetics Institute S.A.Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka
-
Patent number: 7344843Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.Type: GrantFiled: October 14, 2002Date of Patent: March 18, 2008Assignee: Serono Genetics Institute S.A.Inventors: John Lucas, Deno Dialynas, Kristen Briggs